By Connor Hart
Zscaler narrowed its loss and posted higher revenue in its fiscal 1Q, but its current-quarter outlook failed to impress investors. The cloud-security company guided for adjusted earnings between 68 cents a share and 69 cents a share, as well as revenue between $633 million and $635 million, both of which just met analyst expectations. Shares fall 7.8%, to $192.25, in after-hours trading.
Janux Therapeutics' prostate cancer treatment was selected for expansion trials following what the company called encouraging efficacy and safety results. The treatment, called JANX007, resulted in high prostate-specific antigen response rates and deep prostate-specific antigen declines across all doses in a Phase 1a clinical trial. Shares surge 58%, to $63.60, in post-market trading.
TransMedics lowered its full-year outlook. The Andover, Mass., medical-technology company now expects full-year revenue between $428 million and $432 million, down from its previous outlook of between $425 million and $445 million. Analysts surveyed by FactSet are looking for $431.9 million. Shares fall 9.1%, to $77.40, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 02, 2024 18:36 ET (23:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.